Limits...
Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: long-term real-life data from the Lorhen Registry.

Filippini M, Bazzani C, Atzeni F, Sarzi Puttini P, Marchesoni A, Favalli EG, Caporali R, Cavagna L, Gorla R - Biomed Res Int (2014)

Bottom Line: This study involving 1033 patients with RA confirms the effectiveness of etanercept, adalimumab, and infliximab in reducing RA-related disability even in patients with a history of highly active and longstanding RA.Moreover, we found that the improvement in disability was biphasic, with a marked improvement during the first year of anti-TNF therapy, followed by slower but significant recovery over the subsequent four years.

View Article: PubMed Central - PubMed

Affiliation: Rheumatology and Immunology Unit, Spedali Civili di Brescia, Piazza le Spedali Civili 1, 125123 Brescia, Italy.

ABSTRACT
This study involving 1033 patients with RA confirms the effectiveness of etanercept, adalimumab, and infliximab in reducing RA-related disability even in patients with a history of highly active and longstanding RA. Moreover, we found that the improvement in disability was biphasic, with a marked improvement during the first year of anti-TNF therapy, followed by slower but significant recovery over the subsequent four years.

Show MeSH
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4109221&req=5

Mentions: The final study population consisted of 1033 patients (847 females, 186 males) whose baseline clinical and demographic characteristics are shown in Tables 1 and 2. At the end of the study, 42% of the patients were still receiving an anti-TNFα agent (Figure 3). Disability as assessed on the basis of their HAQ scores significantly decreased in all cases (ΔHAQ −0.78; P < 0.05): at the end of the followup, the HAQ score was 0.69 (mild disability) as against 1.42 at baseline (moderate disability). Furthermore, 193/904 patients (21.35%) had no disability (HAQ < 0.5) after one year and 123/344 (35.75%) after five years of followup.


Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: long-term real-life data from the Lorhen Registry.

Filippini M, Bazzani C, Atzeni F, Sarzi Puttini P, Marchesoni A, Favalli EG, Caporali R, Cavagna L, Gorla R - Biomed Res Int (2014)

© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4109221&req=5

Mentions: The final study population consisted of 1033 patients (847 females, 186 males) whose baseline clinical and demographic characteristics are shown in Tables 1 and 2. At the end of the study, 42% of the patients were still receiving an anti-TNFα agent (Figure 3). Disability as assessed on the basis of their HAQ scores significantly decreased in all cases (ΔHAQ −0.78; P < 0.05): at the end of the followup, the HAQ score was 0.69 (mild disability) as against 1.42 at baseline (moderate disability). Furthermore, 193/904 patients (21.35%) had no disability (HAQ < 0.5) after one year and 123/344 (35.75%) after five years of followup.

Bottom Line: This study involving 1033 patients with RA confirms the effectiveness of etanercept, adalimumab, and infliximab in reducing RA-related disability even in patients with a history of highly active and longstanding RA.Moreover, we found that the improvement in disability was biphasic, with a marked improvement during the first year of anti-TNF therapy, followed by slower but significant recovery over the subsequent four years.

View Article: PubMed Central - PubMed

Affiliation: Rheumatology and Immunology Unit, Spedali Civili di Brescia, Piazza le Spedali Civili 1, 125123 Brescia, Italy.

ABSTRACT
This study involving 1033 patients with RA confirms the effectiveness of etanercept, adalimumab, and infliximab in reducing RA-related disability even in patients with a history of highly active and longstanding RA. Moreover, we found that the improvement in disability was biphasic, with a marked improvement during the first year of anti-TNF therapy, followed by slower but significant recovery over the subsequent four years.

Show MeSH